Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – The risk of cancer recurrence is increased slightly after laparoscopic rather than open surgical management of uterine cancer, according to study findings reported…
NEW YORK (Reuters Health) – About one in four patients with peripheral T-cell lymphoma (PTCL) who do not respond to or relapse after systemic therapy are likely to…
NEW YORK (Reuters Health) – Women with early-stage estrogen receptor-positive breast cancer fare somewhat better with 2 years of tamoxifen followed by 3 years of anastrozole than with…
NEW YORK (Reuters Health) – Intraoperative complications are similar whether staging of endometrial cancer is performed laparoscopically or by laparotomy, but laparoscopy has the advantage when it comes…
NEW YORK (Reuters Health) – Results of a study suggest that gonadotropin-releasing hormone (GnRH) agonist therapy does not help preserve ovarian function in young women undergoing modern chemotherapy…
NEW YORK (Reuters Health) – In a phase 2 study of maintenance therapy for metastatic colorectal cancer, adding enzastaurin to bevacizumab plus bolus and infusional 5-fluorouracil-leucovorin (LV5FU2) did…
NEW YORK (Reuters Health) – Cervical intraepithelial neoplasia grade 1 (CIN 1) found on biopsy provides no information on the risk of progression to CIN 3 beyond that…
NEW YORK (Reuters Health) – A pooled analysis of two trials indicates that HIV patients with aggressive B-cell non-Hodgkin lymphoma (NHL) fare better with a regimen of rituximab…
NEW YORK (Reuters Health) – Cirrhosis and hepatitis are associated with the occurrence of hepatocellular carcinoma (HCC) in patients with diabetes, and hepatitis C is of particular importance,…
NEW YORK (Reuters Health) The first report of 10-year outcomes of hepatocellular carcinoma treated by percutaneous radio frequency ablation (RFA) indicates that about 1 in 4 patients survive…
